Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

MonumenTAL-2

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma (NCT05050097)

Currently recruiting

MonumenTAL-8

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma (MonumenTAL-8) (NCT06550895)

Currently recruiting

MRDRIVE-ALL

MRDRIVE-ALL: Minimal Residual Disease Driven Intervention in Elderly Acute Lymphoblastic Leukaemia (Trial Not Registered)

Currently recruiting

mRNA-2752

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade (NCT03739931)

No longer recruiting

MRTLE-DB

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 via an Implantable Pump and a Cranial Port and Double Lumen Catheter (CIC) in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04153175)

Currently recruiting

MRTLE-OLE

An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04529954)

Currently recruiting

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma (NCT06478693)

Currently recruiting

MY-PROMPT-2

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (ACTRN12622001199707p)

Currently recruiting

NADINA

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)

No longer recruiting

NADOM

NADOM trial – Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma (NCT05187884)

No longer recruiting

NAVAL-1

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (VT3996-202) (NCT05011058)

Currently recruiting

Nektar 23-358-05

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis (NCT06136741)

No longer recruiting

NeoFOL-R

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial (NeoFOL-R) (ACTRN12624000005550)

Currently recruiting

NIMBLE

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)

Recently completed/closed

NIMBLE-AZD0466

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419)

Currently recruiting

NIVO-LD

Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretroviral therapy (ART): NIVO-LD (NCT05187429)

Currently recruiting

NN9500-4656

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial (NCT05016882)

Currently recruiting

NOTACS

Effect of Nasal High-Flow Oxygen Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled Trial (NCT05308719)

No longer recruiting

OASIS

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species (NCT05101187)

Currently recruiting

OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (NCT05643573)

Currently recruiting
19 20 21 22 23